ClinicalTrials.gov
ClinicalTrials.gov Menu

Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00383773
Recruitment Status : Unknown
Verified September 2006 by Hadassah Medical Organization.
Recruitment status was:  Not yet recruiting
First Posted : October 4, 2006
Last Update Posted : October 4, 2006
Sponsor:
Information provided by:
Hadassah Medical Organization

Brief Summary:
Patients with Central Retinal Vein Occlusion will undergo vitrectomy, a small needle of about 71 micron will enter a branch retinal vein and TPA will be injected into the obstracted vein.

Condition or disease Intervention/treatment Phase
Central Retinal Vein Occlusion Procedure: Retinal endo vascular surgery Not Applicable

Detailed Description:

Patients with Central Retinal Vein Occlusion less than 6 month duration and reduction of vision to 6/21 will go OCT and FANG examinations.

Patient will be operated vitrectomy, and a branch retinal vein will be punctured by small needle and rTPA 200mcg/ml will be injected to the vein.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : October 2006
Estimated Study Completion Date : October 2007



Primary Outcome Measures :
  1. Visual acuity
  2. Amount of macular edema.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • crvo less than 6 month
  • Visual Acuity less than 6/21
  • No prior eye surgery except cataract.

Exclusion Criteria:

  • Retinal/iris neovascularization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00383773


Contacts
Contact: Michael Halpert, MD. 00972507874385 halpert@cc.huji.ac.il
Contact: Hadas Lemberg, PhD 0097226777572 Ihadas@hadassah.org.il

Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Study Chair: Michael halpert Hadassah Medical Organization

ClinicalTrials.gov Identifier: NCT00383773     History of Changes
Other Study ID Numbers: 1yumbo-HMO-CTIL
First Posted: October 4, 2006    Key Record Dates
Last Update Posted: October 4, 2006
Last Verified: September 2006

Keywords provided by Hadassah Medical Organization:
retinal vein occlusion
rTPA

Additional relevant MeSH terms:
Retinal Vein Occlusion
Retinal Diseases
Eye Diseases
Venous Thrombosis
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases